SCHEMBL4868239

SCHEMBL4868239

COc1cc(CNc2nc(-c3ccccc3)nc3ccccc23)ccc1O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.81
KMT2A Q03164 6/20 0.81
PDE5A O76074 4/20 0.62
GBA1 P04062 1/20 0.62
ATM Q13315 1/20 0.62
LMNA P02545 4/20 0.61
CYP1A2 P05177 4/20 0.61
CYP3A4 P08684 4/20 0.61
CYP2D6 P10635 4/20 0.61
TSHR P16473 4/20 0.61
CYP2C19 P33261 4/20 0.61
USP2 O75604 3/20 0.61
CYP2C9 P11712 3/20 0.61
MAPK1 P28482 2/20 0.61
HSD17B10 Q99714 2/20 0.61
ALDH1A1 P00352 1/20 0.61
CLK4 Q9HAZ1 1/20 0.61
MAPT P10636 2/20 0.60
APP P05067 4/20 0.59
SMN1; SMN2 Q16637 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083760 0.90 MEN1 (1.00) MEN1KMT2APDE5AGBA1ATM
SCHEMBL4868213 0.85 MEN1 (0.79) MEN1KMT2APDE5AGBA1ATM
SCHEMBL7280346 0.81 KMT2A (0.82) MEN1KMT2APDE5AGBA1LMNA
SCHEMBL4865131 0.81 CYP1A2 (0.87) MEN1KMT2APDE5AGBA1ATM
SCHEMBL4867805 0.80 CYP1A2 (0.74) MEN1KMT2APDE5AGBA1ATM
SCHEMBL2291454 0.79 LMNA (0.66) MEN1KMT2APDE5AGBA1ATM
SCHEMBL4859994 0.79 CYP1A2 (0.81) MEN1KMT2APDE5AGBA1ATM
SCHEMBL4864236 0.79 MEN1 (0.69) MEN1KMT2APDE5AGBA1ATM
SCHEMBL12176090 0.79 LMNA (0.72) MEN1KMT2APDE5AGBA1ATM
SCHEMBL1083823 0.79 MEN1 (0.79) MEN1KMT2APDE5ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MEN1 3837/4885KMT2A 1662/4885PDE5A 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.